Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- PDCD-1 B7H1 HEK-293 PDL1 B-7 Homolog 1 CD-274 IFN? PDCD1L1 PDCD1LG1 non-hematopoietic
- Product Overview:
Programmed cell death 1 ligand 1 (PD-L1), also known as B7-H1 or CD274, is a B7 family protein that is involved in regulation and attenuation of the adaptive immune response and peripheral T cell tolerance.{53691,52533,53686,53693} It is a 290-amino acid type I transmembrane protein encoded by the CD274 gene in humans and is comprised of a 239-amino acid extracellular domain consisting of a signal peptide, an IgV-like domain, and an IgC-like domain, a transmembrane domain, and a cytoplasmic tail.{53691,53692} PD-L1 is constitutively expressed in T and B cells, dendritic cells, macrophages, and regulatory T cells (Tregs), as well as a variety of nonhematopoietic cells and is upregulated by IFN-?.{53686} Binding of PD-L1 to its receptor, programmed cell death protein 1 (PD-1; Item No. 28377), suppresses T cell proliferation, migration, and cytokine production.{52533,53693} PD-L1 is also aberrantly expressed in a variety of tumor cells, and expression of PD-L1 in tumor tissue is associated with poor prognosis in patients with renal cell carcinoma. {53690,53688,53694} Formulations containing PD-L1 blocking antibodies have been used in the treatment of a variety of cancers. Cayman’s PD-L1 Extracellular Domain (human, recombinant) protein can be used for ELISA, binding assay, and cell-based assay applications. This protein is a disulfide-linked homodimer. The reduced monomer, comprised of PD-L1 (amino acids 19-239) fused to mouse IgG1 Fc at its C-terminus, consists of 455 amino acids, has a calculated molecular weight of 51.7 kDa, and a predicted N-terminus of Phe19 after signal peptide cleavage. As a result of glycosylation, the monomer migrates at approximately 66 kDa by SDS-PAGE under reducing conditions.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.